文献速递免疫规划慢病防控与筛查

治疗后癌症幸存者的疫苗接种率:多疫苗范围综述

Vaccination uptake among post-treatment cancer survivors: A multi-vaccine scoping review.
PubMed 文献 · Vaccine · 2024-05-27

本范围综述遵循PRISMA指南,检索Ovid MEDLINE、Embase和CINAHL数据库2011至2021年英文文献,最终纳入31项研究,覆盖流感、人乳头瘤病毒、肺炎球菌等多种疫苗。结果显示疫苗接种率在不同研究、疫苗类型和人群间差异很大,影响因素包括社会人口学变量、健康信念/态度/知识、提供者推荐及癌症治疗/临床变量。作者强调需进一步研究接种相关因素、制定针对癌症幸存者的临床指南,并探索多水平干预措施以提高接种率。

要点

  • 31项研究覆盖流感、人乳头瘤病毒、肺炎球菌等疫苗接种率,差异很大
  • 影响因素包括社会人口学、健康信念/知识、提供者推荐及治疗相关变量
  • 作者认为需进一步研究接种因素并制定癌症幸存者疫苗接种指南

核心结论

  • 作者认为需进一步研究疫苗接种相关因素,需制定专门针对癌症幸存者疫苗接种的临床指南,并指出多水平干预的潜在目标以提高该人群接种率。

研究设计与样本

  • 范围综述,遵循PRISMA指南,检索Ovid MEDLINE ALL、Embase和CINAHL Complete数据库。
  • 纳入标准为2011至2021年发表的英文文章,研究对象为完成治疗的癌症幸存者,报告疫苗接种率及与接种相关的因素(如障碍和促进因素)。
  • 检索共返回4215篇文章,去除271篇重复后,摘要/标题筛选识别212篇,全文筛选后47篇符合纳入标准,排除16篇,最终纳入31项研究。

主要发现

  • 31项研究中参与者年龄从9岁到各年龄段成人。
  • 疫苗类型包括流感(n=18)、人乳头瘤病毒(n=10)、肺炎球菌(n=8)、甲/乙型肝炎(n=1)、带状疱疹(n=1)、麻疹(n=1)、破伤风/白喉(n=1)和B型流感嗜血杆菌(n=1)。
  • 疫苗接种率在不同研究、疫苗类型和参与者人群间差异很大。
  • 影响接种的因素包括社会人口学变量和健康的社会决定因素、健康信念/态度/知识、提供者推荐以及癌症治疗/临床变量。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Our goal was to provide an overview of uptake rates across vaccine types and factors associated with vaccine uptake among cancer survivor populations. METHODS: A literature search was conducted using Ovid MEDLINE® ALL (Wolters Kluwer), Embase (Elsevier) and CINAHL Complete (EBSCO) databases and according to PRISMA guidelines. Eligible articles were limited to those examining vaccination uptake among cancer survivors who had completed treatment, reported factors associated with uptake (e.g., barriers and facilitators), and published in English between 2011 and 2021. Two independent reviewers screened citations for inclusion and two performed data abstraction, verified by an arbiter. RESULTS: The search returned 4,215 total articles, and 271 duplicates were removed. During abstract/title screening, 212 articles were identified. Following full-text screening, 47 articles/abstracts were found to meet inclusion criteria, 16 articles/abstracts were removed, and 31 studies were included in the review. Among the 31 studies, participant age ranged from 9 years to adults of all ages. Vaccine types included: influenza (n = 18), human papillomavirus (n = 10), pneumococcal (n = 8), hepatitis A/B (n = 1), shingles (n = 1), measles (n = 1), tetanus/diphtheria (n = 1), and haemophilus influenza B (n = 1). Vaccine uptake varied greatly across studies, vaccine types, and participant populations. Factors affecting vaccination uptake included sociodemographic variables and social determinants of health, health beliefs/attitudes/knowledge, provider recommendation, and cancer treatment/clinical variables. CONCLUSIONS: Our findings highlight the need for further examining factors associated with vaccine uptake, the need for clinical guidelines that specifically address vaccination among cancer survivors, and potential targets for multi-level interventions to improve vaccination rates among cancer survivor populations.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Renduchintala K, Arevalo M, Fonseca G, et al. Vaccination uptake among post-treatment cancer survivors: A multi-vaccine scoping review. Vaccine. 2024. PMID: 38802291. doi:10.1016/j.vaccine.2024.05.043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。